BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 420
- Registration Number
- NCT03967977
- Locations
- 🇨🇳
Chinese Pla General Hospital, Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
- Interventions
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 370
- Registration Number
- NCT03957590
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳The First Affiliated Hospitalschool of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
🇨🇳Jieyang Peoples Hospital (Jieyang Affiliated Hospital, Sun Yat Sen University ), Jieyang, Guangdong, China
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
- Conditions
- Carcinoma, HepatocellularGastric/Gastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 111
- Registration Number
- NCT03941873
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
- Conditions
- Recurrent or Metastatic Nasopharyngeal Cancer
- Interventions
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 263
- Registration Number
- NCT03924986
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 93
- Registration Number
- NCT03905148
- Locations
- 🇺🇸
University of California Los Angeles, Santa Monica, California, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇦🇺Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 68
- Registration Number
- NCT03846427
- Locations
- 🇺🇸
Clinical Research Alliance, Inc, Westbury, New York, United States
🇺🇸The Charlotte Mecklenburg Hospital Authority, Charlotte, North Carolina, United States
🇦🇺The Saint George Hospital Kogarah, Kogarah, New South Wales, Australia
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 649
- Registration Number
- NCT03783442
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳Anhui Medical University - The Second Hospital, Hefei, Anhui, China
🇨🇳Xiangyang Central Hospital, Xiangyang, Hubei, China
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
- Conditions
- Gastric, or Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 997
- Registration Number
- NCT03777657
- Locations
- 🇨🇳
Foshan First Peoples Hospital, Foshan, Guangdong, China
🇨🇳Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors
- Conditions
- Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2
- Interventions
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 114
- Registration Number
- NCT03744468
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 200
- Registration Number
- NCT03736889
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The Affiliated Hospital of Military Medical Sciences, Beijing, Beijing, China
🇨🇳Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China